AVEO - Aveo Pharmaceuticals Inc.

Aveo Pharmaceuticals Inc. (AVEO) is a biopharmaceutical company that is focused on developing targeted cancer therapies. The company's lead product candidate, tivozanib, is a potent and selective vascular endothelial growth factor receptor tyrosine kinase inhibitor that is being developed for the treatment of renal cell carcinoma and other solid tumors.

As of its last market close, AVEO had a market capitalization of approximately $240 million USD. The company had a trailing twelve-month revenue of approximately $0.7 million USD and a net loss of approximately $25 million USD. AVEO's stock price had a 52-week range of $2.00 - $15.97 USD and was trading at approximately $3.19 USD at the time of its last market close.

Aveo Pharmaceuticals faces a number of risks associated with developing and commercializing new drug products, including the risks of clinical trial failure, regulatory hurdles, competition, and changes in market conditions. The company's financial performance is also subject to risks associated with its ability to secure financing and manage expenses. Investors should carefully consider these risks before making any investment decisions.

Stock Sector: Drugs: Biotechnology